Lantheus Holdings to Present at the 4th Annual Evercore ISI HealthCONx ConferenceGlobeNewsWire • 11/16/21
Lantheus Holdings, Inc. (LNTH) CEO Mary Anne Heino on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/06/21
Lantheus Holdings to Host Third Quarter 2021 Earnings Conference Call and Webcast on November 4, 2021 at 8:00 a.m. Eastern TimeGlobeNewsWire • 10/21/21
Lantheus and RefleXion Announce Development and Commercialization Collaboration with the Potential to Improve Future Prostate Cancer TreatmentGlobeNewsWire • 09/13/21
Lantheus Announces Presentation at the 2021 American Urological Association (AUA) Annual MeetingGlobeNewsWire • 09/10/21
Lantheus Announces the First and Only FDA Cleared AI-Enabled PSMA Digital Application, aPROMISE™, Strengthening Lantheus' Leadership in Prostate CancerBusiness Wire • 07/29/21
Lantheus Holdings, Inc. (LNTH) CEO Mary Anne Heino on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 07/28/21
Analysts Estimate Lantheus Holdings (LNTH) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 07/21/21
Lantheus Holdings to Host Second Quarter 2021 Earnings Conference Call and Webcast on July 28, 2021 at 8:00 a.m. Eastern TimeBusiness Wire • 07/14/21
Lantheus To Present Piflufolastat F 18 Data at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2021 Annual MeetingBusiness Wire • 06/14/21
Lantheus Holdings (LNTH) Soars 16.8%: Is Further Upside Left in the Stock?Zacks Investment Research • 05/28/21
Lantheus Shares Trading Higher On FDA Approval For Imaging Agent For Identification Of Prostate CancerBenzinga • 05/27/21
Lantheus Receives U.S. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent for Prostate CancerBusiness Wire • 05/27/21
Lantheus Holdings Announces Presentation Featuring 18F-DCFPyL PET/CT, its PSMA-Targeted Prostate Cancer Imaging Agent at the 2021 ASCO Annual MeetingBusiness Wire • 05/21/21